New directions in the pharmacotherapy of posttraumatic stress disorder

Psychiatric Quarterly

Volumn 73, Issue 4, 2002, Pages 259-270

  Marmar, Charles R ^a   Neylan, Thomas C ^a   Schoenfeld, Frank B ^a  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

New directions; Psychopharmacology for PTSD

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPRAZOLAM; ANTIDEPRESSANT AGENT; BROFAROMINE; BUSPIRONE; CARBAMAZEPINE; CLONAZEPAM; CLONIDINE; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; GUANFACINE; LITHIUM CARBONATE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; PAROXETINE; PLACEBO; PRAZOSIN; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VALPROIC ACID; VENLAFAXINE;

ACUTE DISEASE; ADOLESCENT; ADRENERGIC ACTIVITY; ANXIETY; AROUSAL; BEHAVIOR THERAPY; BONE MARROW DEPRESSION; BRADYCARDIA; CHILD; CHRONIC DISEASE; COGNITIVE THERAPY; CONFERENCE PAPER; DEPENDENT PERSONALITY DISORDER; DIZZINESS; DROWSINESS; FATIGUE; HEADACHE; HUMAN; HYPOTENSION; INSOMNIA; LIVER FAILURE; NAUSEA; NERVOUSNESS; NIGHTMARE; POLYSOMNOGRAPHY; POLYURIA; POSTTRAUMATIC STRESS DISORDER; PSYCHOPHARMACOLOGY; QUALITY OF LIFE; RESTLESSNESS; SEDATION; SURVIVAL; TREMOR; VERTIGO; VOMITING; WEIGHT GAIN; XEROSTOMIA; REVIEW;

ACUTE DISEASE; ADOLESCENT; ADRENERGIC ANTAGONISTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CHILD; CHRONIC DISEASE; HUMANS; STRESS DISORDERS, POST-TRAUMATIC;

EID: 0036887020     PISSN: 00332720     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020459916113     Document Type: Article

References (48)

1. Neal LA, Shapland W, Fox C: An open trial of moclobemide in the treatment of posttraumatic stress disorder. International Clinical Psychopharmacology 12:231-237, 1997.
2. Amital D, Zohar J, Bleich A: A placebo-controlled pilot study of sertraline in posstraumatic stress disorder [poster]. Paper presented at Collegium Internationale Neuro-Psychopharmacologicum annual meeting, Brussels, Belgium, 2000.
3. Davidson JR, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel G: Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Archives of General Psychiatry 58:485-492, 2001.
4. Brady K, Pearlstein T, Asnis GM, et al: Efficacy and safety of sertraline treatment of posttraumatic stress disorder: A randomized controlled trial. JAMA 283:1837-1844, 2000.
5. Marmar CR, Schoenfeld FB, Weiss DS, Metzler TJ, Zatzick D, Wu R, et al: Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder. Journal of Clinical Psychiatry 57(Suppl 8):66-72, 1996.
6. Neylan TC, Metzler TJ, Schoenfeld FB, Weiss DS, Lenoci M, Best SR, et al: Fluvoxamine and sleep disturbances in posttraumatic stress disorder. Journal of Traumatic Stress 14(3):461-468, 2001.
7. van der Kolk BA, Dreyfuss D, Michaels M, Shera D, Berkowitz R, Fisler R, et al: Fluoxetine in posttraumatic stress disorder. Journal of Clinical Psychiatry 55:517-522, 1994.
8. Marshall RD, Schneier FR, Fallon BA, et al: An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder. Journal of Clinical Psychopharmacology 18:10-18, 1998.
9. Beebe K, Pitts C, Ruggiero L, Ramming S, Oldham M, Zaninelli R: Paroxetine in the treatment of PTSD: A 12-week, placebo-controlled, Multicenter Study. Paper presented at ISTSS, San Antonio, TX, 2000.
10. Londborg PD, Hegel MT, Goldstein S, Goldstein D, Himmelhoch JM, Maddock R, et al: Sertraline treatment of posttraumatic stress disorder: Results of 24 weeks of open-label continuation treatmetns. Journal of Clinical Psychiatry 62(5):325-331, 2001.
11. Marshall RD, Beebe KL, Oldham M, Zaninelli R: Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. American Journal of Psychiatry 158(12):1982-1988, 2001.
12. Londborg P, Patterson W, Hegel M, Sikes C, Farfel G: Results of a 24-week Open-Label Extension Study of Sertraline in PTSD [poster]. Paper presented at American Psychiatric Association, Chicago, 2000.
13. Rapaport MH, Endicott J, Clary CM: Posttraumatic stress disorder and quality of life: Results across 64 weeks of sertaline treatment. Journal of Clinical Psychiatry 63(1):59-65, 2002.
14. Davidson J, Pearlstein T, Londborg P, Brady KT, Rothbaum B, Bell J, et al: Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: Results of a 28-week double-blind, placebo-controlled study. American Journal of Psychiatry 158(12):1974-1981, 2001.
15. Hidalgo R, Hertzberg MA, Mellman T, Petty F, Tucker P, Weisler R, et al: Nefazodone in post-traumatic stress disorder: Results from six open-label trials. International Clinical Psychopharmacology 14(2):61-68, 1999.
16. Davis LL, Nugent AL, Murray J, Kramer GL, Petty F: Nefazodone treatment for chronic posttraumatic stress disorder: An open trial. Journal of Clinical Psychopharmacology 20:159-164, 2000.
17. Gillin JC, Smith-Vaniz A, Schnierow B, Rapaport MH, Kelsoe J, Raimo E, et al: An open-label, 12-week clinical and sleep EEG study of nefazodone in chronic Combat-related posttraumatic stress disorder. Journal of Clinical Psychiatry 62(10):789-796, 2001.
18. Baker DG, Diamond BI, Gillette G, Hamner M, Katzelnick D, Keller T, et al: A double-blind, randomized, placebo-controlled, multi-center study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology 122(4):386-389, 1995.
19. Katz RJ, Lott MH, Arbus P, et al: Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic. Anxiety 1:169-174, 1995.
20. Hamner MB, Frueh B: Response to venlafaxine in a previously antidepressant treatment-resistant combat veteran with post-traumatic stress disorder. International Clinical Psychopharmacol 13:233-234, 1998.
21. Gelpin E, Bonne O, Peri T, Brandes D, Shalev A: Treatment of recent trauma survivors with benzodiazepines: A prospective study. Journal of Clinical Psychiatry 57:390-394, 1996.
22. Braun P, Greenberg D, Dasberg H, Lerer B: Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. Journal of Clinical Psychiatry 51:236-238, 1990.
23. Risse SC, Whitters A, Burke J, Chen S, Scurfield RM, Raskind MA: Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced posttraumatic stress disorder. Journal of Clinical Psychiatry 51:206-209, 1990.
24. Kaplan HI, Sadock B: Synopsis of Psychiatry, 8th edn., Baltimore, MD, Lippincott Williams & Wilkins, 1998.
25. Duffy JD, Malloy PF: Efficacy of buspirone in the treatment of posttraumatic stress disorder: An open trial. Annals of Clinical Psychiatry 6:33-37, 1994.
26. Lipper S, Davidson JR, Grady TA, et al: Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics 27:849-854, 1986.
27. Keck PE, Jr., McElroy SL, Friedman LM: Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. Journal of Clinical Psychopharmacology 12(1):36S-41S, 1992.
28. Looff D, Grimley P, Kuller F, Martin A, Shonfield L: Carbamazepine for ptsd [letter]. Journal of the American Academy of Child and Adolescent Psychiatiy 34(6):703-704, 1995.
29. Fesler FA: Valproate in combat-related posttraumatic stress disorder. Journal of Clinical Psychiatry 52:361-364, 1991.
30. Berlant JvK: Open-label topiramate as primary or adjunctive therapy in chronic civillian posttraumatic stress disorder: A preliminary report. Journal of Clinical Psychiatry 63(1):15-20, 2002.
31. Forster PL, Schoenfeld FB, Marmar CR, Lang AJ: Lithium for irritability in posttraumatic stress disorder. Journal of Traumatic Stress 8:143-149, 1995.
32. Petty F, Brannan S, Casada J, LL D, Gajewski V, GL K, et al: Olanzapine treatment for post-traumatic stress disorder: An open-label study. International Clinical Psychopharmacy 16(6):331-337, 2001.
33. Southwick S, Paige S, Morgan C, Bremner J, Krystal JH, Charney DS: Neurotransmitter alterations in PTSD: Catecholamines and serotonin. Seminar in Clinical Neuropsychiatry 4:242-248, 1999.
34. Cahill L, Prins B, Weber M, JL. M: Beta-adrenergic activation and memory for emotional events. Nature 371:702-704, 1994.
35. Pitman RK, Sanders KM, Zusman RM, Healy AR, Cheema F, Lasko NB, et al: Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biological Psychiatry 51(2):189-192, 2002.
36. Famularo R, Kinscherff R, Fenton T: Propranolol treatment for childhood posttraumatic stress disorder, acute type. A pilot study. American Journal of Diseased Children 142:1244-1247, 1988.
37. Friedman MJ, Southwick SM: Towards pharmacotherapy for post-traumatic stress disorder. In: M. J. Friedman, D. S. Charney, and A. Y. Deutch, eds., Neurobiological and Clinical Consequences of Stress: From Normal Adaptation to Post-Traumatic Stress Disorder. Philadelphia, PA, Lippincott-Raven Publishers, 1995, pp. 465-481.
38. Harmon RJ, Riggs P: Clonidine for posttraumatic stress disorder in preschool children. Journal of the American Academy of Child and Adolescent Psychiatry 35:1247-1249, 1996.
39. Kinzie JD, Leung P: Clonidine in Cambodian patients with posttraumatic stress disorder. Journal of Nervous Mental Disease 177:546-550, 1989.
40. Horrigan JP, Barnhill LJ: The suppression of nightmares with guanfacine. Journal of Clinical Psychiatry 57(8):371, 1996.
41. Mellman TA, David D, Barza L: Nefazodone treatment and dream reports in chronic PTSD. Depression and Anxiety 9:146-148, 1999.
42. Gupta S, Austin R, Cali LA, Bhatara V: Nightmares treated with cyproheptadine. Journal of the American Academy of Child and Adolescent Psychiatry 37(6):570-571, 1998.
43. Rijnders R, Laman DM, Van Diujn H: Cyproheptadine for posttraumatic nightmares. American Journal of Psychiatry 157:1524-1525, 2000.
44. Hamner MB, Brodrick PS, Labbate LA: Gabapentin in PTSD: A retrospective, clinical series of adjunctive therapy. Annals of Clinical Psychiatry 13(3): 141-146, 2001.
45. Raskind M, Dobie D, Kanter E, Petrie E, Thompson C, Peskind E: The alphal-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stres disorder: A report of 4 cases. Journal of Clinical Psychiatry 61(2):129-133, 2000.
46. Donnelly CL, Amaya-Jackson L, March J: Psychopharmacology of pediatric posttraumatic stress disorder. Journal of Child and Adolescent Psychopharmacology 9:203-220, 1999.
47. Robert R, Blakeney PE, Villarreal C, Rosenberg L, 3rd MW: Imipramine treatment in pediatric burn patients with symptoms of acute stress disorder: A pilot study. Journal of the American Academy of Child and Adolescent Psychiatry 38:873-882, 1999.
48. Shalev AY, Bonne O: Pharmacological treatment of trauma-related disorders. In: Shalev AY, Yehuda R, McFarlane, eds., International Handbook of Human Response to Trauma. New York, Kluwer Academic/Plenum Publishers, 2000, pp. 363-378.